Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

15.62
-0.5700-3.52%
Post-market: 15.10-0.5200-3.33%19:59 EST
Volume:1.93M
Turnover:29.97M
Market Cap:2.53B
PE:-4.31
High:16.01
Open:15.72
Low:15.10
Close:16.19
52wk High:25.00
52wk Low:6.36
Shares:162.00M
Float Shares:152.00M
Volume Ratio:0.92
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6224
EPS(LYR):-3.3716
ROE:-60.66%
ROA:-34.32%
PB:3.66
PE(LYR):-4.63

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart

Reuters
·
Dec 09, 2025

Dyne Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 08, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix

Reuters
·
Dec 08, 2025

Dyne Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $60 From $46

THOMSON REUTERS
·
Dec 08, 2025

BRIEF-Dyne Therapeutics Announces Positive Topline Results From Phase 1/2 Deliver Trial

Reuters
·
Dec 08, 2025

Dyne Therapeutics Shares up 3.6% Premarket After Co Reports Early-to-Mid Stage Trial Data for Muscle Disorder Drug

THOMSON REUTERS
·
Dec 08, 2025

BUZZ-Dyne Therapeutics rises after positive data for its muscle wasting drug

Reuters
·
Dec 08, 2025

Dyne Therapeutics Inc - Submission for U.S. Accelerated Approval on Track for Q2 2026

THOMSON REUTERS
·
Dec 08, 2025

Dyne Therapeutics Inc: Registrational Expansion Cohort (Rec) Met Primary Endpoint

THOMSON REUTERS
·
Dec 08, 2025

Dyne Therapeutics Announces Positive Topline Results From Phase 1/2 Deliver Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (Dmd)

THOMSON REUTERS
·
Dec 08, 2025

Dyne Therapeutics Inc - Rec Shows Significant Increase in Dystrophin Expression to 5.46%

THOMSON REUTERS
·
Dec 08, 2025

Dyne Therapeutics Inc - Z-Rostudirsen Shows Favorable Safety Profile

THOMSON REUTERS
·
Dec 08, 2025

Dyne Therapeutics Announces Topline Results from DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy

Reuters
·
Dec 08, 2025

Dyne Therapeutics Chief Medical Officer Douglas Kerr Reports Sale of Common Shares

Reuters
·
Dec 06, 2025

Dyne Therapeutics Chief Commercial Officer Johanna Friedl-Naderer Reports Sale of Common Shares

Reuters
·
Dec 06, 2025

Dyne Therapeutics (DYN): Evaluating Valuation Following Promising Clinical Results and New Regulatory Designation

Simply Wall St.
·
Nov 28, 2025

Dyne Therapeutics price target raised to $21 from $12 at Bernstein

TIPRANKS
·
Nov 25, 2025

Dyne Therapeutics Inc : Bernstein Raises Target Price to $21 From $12

THOMSON REUTERS
·
Nov 25, 2025

Dyne Therapeutics Is Maintained at Neutral by JP Morgan

Dow Jones
·
Nov 15, 2025

U.S. RESEARCH ROUNDUP-Disney, Enanta Pharmaceuticals, Phillips 66

Reuters
·
Nov 14, 2025